CRISPR Therapeutics AG (CRSP) Financials
CRSP Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 2.2 billion | 346.8 million |
2023-09-30 | 2.1 billion | 359.0 million |
2023-06-30 | 2.2 billion | 381.0 million |
2023-03-31 | 2.2 billion | 389.5 million |
CRSP Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -96.8 million | 18.4 million |
2023-09-30 | -42.0 million | 20.0 million |
2023-06-30 | -136.8 million | 21.8 million |
2023-03-31 | 5.7 million | 20.9 million |
CRSP Net Income
No data available :(
CRSP Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 1.7 billion | - | 238.6 million |
2023-09-30 | 1.7 billion | - | 241.6 million |
2023-06-30 | 1.8 billion | - | 245.2 million |
2023-03-31 | 344.4 million | - | 240.3 million |
CRSP Shares Outstanding
CRSP Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 738000 | 95.1 million | 16.5 million | - |
2023-09-30 | 2.1 million | 90.7 million | 18.3 million | - |
2023-06-30 | 3.6 million | 101.6 million | 19.0 million | - |
2023-03-31 | 3.1 million | 99.9 million | 22.4 million | - |
CRSP Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 200.0 million | 20.0 million |
2023-09-30 | - | 23.4 million |
2023-06-30 | 70.0 million | 44.6 million |
2023-03-31 | 100.0 million | 42.2 million |
CRSP
Price: $55.07
52 week price:
Earnings Per Share: -1.94 USD
P/E Ratio: -15.08
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.2 million
Ebitda: -23.2 millionMarket Capitalization: 5.0 billion